Antiplatelets
- Prevent platelet-rich arterial thrombosis
- Aspirin + P2Y12 dominate ACS/PCI care
- Aspirin: irreversible COX-1 inhibition
- P2Y12 drugs differ in potency + reversibility
- Bleeding is the dominant class toxicity
- Little role for treatment of venous thrombosis
- Duration depends on ischemic vs bleeding risk
Class at a glance
- Prevent platelet-rich arterial thrombosis
Pharmacology
- Aspirin: irreversible COX-1 inhibition
- P2Y12 drugs differ in potency + reversibility
Clinical role
- Aspirin + P2Y12 dominate ACS/PCI care
- Little role for treatment of venous thrombosis
Safety / monitoring
- Bleeding is the dominant class toxicity
- Duration depends on ischemic vs bleeding risk
Self-check
- What determines antiplatelet duration?
Ischemic versus bleeding risk. - What is the dominant antiplatelet toxicity?
Bleeding.
Drugs in this class (5)
Antiplatelets prescription history
Animated chart of estimated U.S. prescriptions per year, Antithrombotics (1914–2026). P2Y12 inhibitors highlighted from 1991.
All drug classes · Open Antiplatelets in the interactive console ↗